Consensus and modeling guidance
Modeling guidance
Clariant targets a Capex spend of ~ CHF 150 - 175 million Swiss francs in 2026.
Clariant targets to defend a solid investment rating.
Clariant targets to create value for shareholders by achieving above-average returns and distributing a stable or rising dividend.
CHF 69 m of CHF 100 m targeted run-rate cost savings achieved as of HY 2026; total expectation of CHF 90 million in FY 2026, with remainder expected in 2027.
Divestments and closures create a negative top-line impact of 1 % ( Group) and 2 % (Care Chemicals) to 2026 sales.
For FY 2026, Clariant expects 3 - 5 % headwind on sales.
As of Q2 2026, Clariant expects
- raw material cost to go high single-digit percent up,
- energy costs to go high single-digit percent up, and
- logistic cost to go double-digit percent up.
Clariant expects continued challenging and volatile market conditions with geopolitical challenges, uncertainties and risks for the full year 2026.
The conflict in the Middle East will continue to impact orders in the Catalysts and Oil Services (Care Chemicals) businesses. Clariant continues to drive its proven value-based price management in order to mitigate the significant annualized cost inflation in raw material, energy and logistic costs, supported by its global production network.
Clariant therefore continues to expect sales in local currency to be around flat as it looks to offset a negative top-line impact for the Group of 1 % (2 % in Care Chemicals) from its portfolio pruning in the prior year. Growth is expected in Adsorbents & Additives with slight underlying growth in Care Chemicals, while sales in Catalysts are now expected to be below the levels of 2025.
Clariant expects an EBITDA margin before exceptional items of around 18 % in 2026.
For FY 2026, Clariant assumes a tax rate of 27 - 29 % due to the earnings distribution globally.
Consensus
Disclaimer: Consensus earnings estimates are based on earnings projections made by equity analysts who cover Clariant. Any opinions, forecasts, estimates, projections or predictions regarding Clariant’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Clariant or its management. Clariant does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. Clariant assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.
Contact us
Clariant’s Investor Relations team is committed to an open and fair dialogue with all of its stakeholders. Please contact us.